跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 13,957 条关于
“TYK2/JAK1 inhibitors”
全部
13,957
临床试验
6,453
药物
3,244
机构
10
资讯
4,250
去年
Sareum Partners with Receptor.AI to Accelerate AI-Driven Discovery of Brain-Penetrating TYK2/JAK1 Inhibitors for Neuroinflammatory Diseases
去年
Priovant Eyes Broad Autoimmune Applications for Brepocitinib After Promising Phase II Results
2个月前
Sareum Completes Dosing in Phase 2-Enabling Toxicology Programme for TYK2/JAK1 Inhibitor SDC-1801
去年
Accropeutics' Oral TYK2/JAK1 Inhibitor Shows Strong Efficacy in Phase 2 Psoriasis Trial
去年
Sareum Holdings Raises £2.4 Million to Advance TYK2/JAK1 Inhibitor SDC-1801
去年
Accro Bioscience to Present Positive Phase II Results for AC-201 TYK2/JAK1 Inhibitor in Plaque Psoriasis at EADV Congress
去年
Fosun Pharma Secures Exclusive Rights to Accro's TYK2/JAK1 Inhibitor AC-201 for Greater China in $21.8M Deal
去年
Zasocitinib: AI-Designed TYK2 Inhibitor Shows Promise in Psoriasis and Psoriatic Arthritis Treatment
10天前
Accro Bioscience Announces NMPA Clearance for Phase II/III Trial of AC-201, a Selective TYK2/JAK1 Inhibitor for Non-Segmental Vitiligo
去年
Biohaven Initiates Pivotal Phase II/III Trial of Brain-Penetrant TYK2/JAK1 Inhibitor BHV-8000 for Early Parkinson's Disease
第 1 页,共 425 页
上一页
下一页